Classification of Beta-Blockers
Classification into generations is based on $\beta_1$-receptor selectivity and the presence of additional vasodilating properties.
- 1st Generation (Non-selective). Block both $\beta_1$- and $\beta_2$-receptors. A typical representative is propranolol, which has high lipophilicity and membrane-stabilizing activity (MSA). This group also includes nadolol (hydrophilic, no MSA) and pindolol (amphiphilic, with intrinsic sympathomimetic activity [ISA]).
- 2nd Generation (Cardioselective). Act preferentially on $\beta_1$-receptors. These include metoprolol (lipophilic, weak MSA), atenolol (hydrophilic, no additional properties), bisoprolol (amphiphilic, high selectivity), and betaxolol.
- 3rd Generation (Vasodilating). Possess vasodilating capabilities. Nebivolol stimulates nitric oxide (NO) production. Carvedilol blocks $\alpha_1$-adrenergic receptors. Celiprolol features a complex mechanism: $\alpha_2$-receptor blockade, $\beta_2$-receptor stimulation, and NO release.
Lipophilicity and Hydrophilicity
Physicochemical properties determine the pharmacokinetics of these drugs.
- Lipophilic agents (e.g., propranolol, metoprolol, carvedilol). Well absorbed, but have low bioavailability due to a significant first-pass hepatic metabolism. Protein-bound and metabolized by the liver. Easily cross the blood-brain barrier (BBB), which can lead to central nervous system (CNS) side effects such as depression and sleep disturbances.
- Hydrophilic agents (atenolol, nadolol). Incompletely absorbed, minimally metabolized by the liver, and primarily excreted by the kidneys. Do not cross the BBB.
- Amphiphilic agents (bisoprolol, pindolol, celiprolol). Dissolve in both water and lipids. Exhibit a balanced elimination pathway (hepatic + renal).
Dosing Considerations and Metabolism
When prescribing beta-blockers, the status of elimination organs must be considered:
- In liver disease or decreased hepatic blood flow, the dose of lipophilic drugs must be adjusted.
- In renal impairment (and in elderly patients), a dose reduction of hydrophilic agents is required to prevent drug accumulation.
- Pharmacogenetics is crucial: the metabolism of certain lipophilic drugs (metoprolol, carvedilol, nebivolol) depends on the CYP2D6 enzyme. Genetic polymorphisms can lead to slow metabolism, increased bioavailability, and a higher risk of adverse effects. Doses should be reduced accordingly.
- The duration of action depends on the half-life ($T_{1/2}$). Long-acting agents (bisoprolol, atenolol, carvedilol, nadolol, betaxolol) are administered 1–2 times daily, while short- and intermediate-acting agents (propranolol, metoprolol) are taken more frequently. Esmolol has a short $T_{1/2}$ of about 10 minutes and is used for acute situations.